Major Depressive Disorder

Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform

by

Alto Neu­ro­science Rais­es $35M Series B Financ­ing (Fins­Mes):

Alto Neu­ro­science, a Los Altos, CA-based neu­ro-tech com­pa­ny which spe­cial­izes in pre­ci­sion psy­chi­a­try, rais­es $35M Series B Financ­ing … The com­pa­ny intends to use the funds to advance lead can­di­dates into Phase 2b stud­ies in major depres­sive dis­or­der … Pro­ceeds from the financ­ing will also be used to progress the company’s arti­fi­cial intel­li­gence-enabled brain bio­mark­er plat­form and launch new clin­i­cal tri­als in areas of high unmet med­ical need. Alto will report Phase 2a data in ear­ly 2023 and fur­ther antic­i­pates Phase 2b data read­outs by ear­ly 2024. [Read more…] about Pre­ci­sion psy­chi­a­try pio­neer Alto Neu­ro­science rais­es $35M to advance dig­i­tal bio­mark­er-to-treat­ment platform

Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications

by

Neu­rolief wins FDA break­through nod for wear­able neu­ro­mod for depres­sion (Mass Device):

Neu­rolief announced today that it received FDA break­through device des­ig­na­tion for its Reliv­ion DP sys­tem for treat­ing major depression.

Reliv­ion is a wear­able, non-inva­sive, mul­ti-chan­nel brain neu­ro­mod­u­la­tion device designed as an adjunc­tive treat­ment to phar­ma­ceu­ti­cal man­age­ment of major depres­sive dis­or­der (MDD) in adults who haven’t expe­ri­enced sat­is­fac­to­ry improve­ment from anti­de­pres­sant med­ica­tions, accord­ing to a news release. [Read more…] about Neu­ro­mod­u­la­tion device Reliv­ion gets FDA clear­ance to help patients with major depres­sion who don’t ben­e­fit from anti­de­pres­sant medications

Otsuka Pharma and Click Therapeutics enter partnership poised to transform mental healthcare

by

Otsu­ka, Click Ther­a­peu­tics part­ner to cre­ate ther­a­py for men­tal ill­ness (Ver­dict Med­ical Devices):

“Otsu­ka Pharmaceutical’s US divi­sion Otsu­ka Amer­i­ca has part­nered with Click Ther­a­peu­tics to devel­op and com­mer­cialise a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ing major depres­sive dis­or­der (MDD) [Read more…] about Otsu­ka Phar­ma and Click Ther­a­peu­tics enter part­ner­ship poised to trans­form men­tal healthcare

Transcranial Direct Current Stimulation shows early promise to ameliorate depression, especially if combined with other therapies and dosage optimized

by

___

Tran­scra­nial Direct Cur­rent Stim­u­la­tion Promis­ing for Major Depres­sive Dis­or­der (Psy­chi­a­try Advisor):

“Tran­scra­nial direct cur­rent stim­u­la­tion (tDCS) is an inves­tiga­tive modal­i­ty for major depres­sive dis­or­der (MDD) that has shown some promis­ing results. Though it has a while before it is approved by the US Food and Drug Admin­is­tra­tion, clin­i­cians and patients have been clam­or­ing for an effec­tive treat­ment for MDD that is not asso­ci­at­ed with harm­ful adverse effects. [Read more…] about Tran­scra­nial Direct Cur­rent Stim­u­la­tion shows ear­ly promise to ame­lio­rate depres­sion, espe­cial­ly if com­bined with oth­er ther­a­pies and dosage optimized

FDA clears deep transcranial magnetic stimulation device to treat obsessive-compulsive disorder

by

Brain­sWay’s Brain Stim­u­la­tion Device Receives FDA Approval to Treat Obses­sive-Com­pul­sive Dis­or­der (IEEE Spectrum):

“In 2013, Jerusalem-based Brain­sWay began mar­ket­ing a new type of brain stim­u­la­tion device that uses mag­net­ic puls­es to treat major depres­sive disorder.

Now, thanks to pos­i­tive results in a study of 100 patients, the com­pa­ny has received approval from the U.S. Food and Drug Admin­is­tra­tion (FDA) to mar­ket the device for a sec­ond psy­chi­atric condition—obsessive-compulsive dis­or­der (OCD) [Read more…] about FDA clears deep tran­scra­nial mag­net­ic stim­u­la­tion device to treat obses­sive-com­pul­sive disorder

Systematic evidence review finds cognitive behavioral therapy as effective as antidepressant medicines in treating depression

by

mentalhealthtreatmentsDepres­sion: Treat­ment Beyond Med­ica­tion (The Dana Foundation):

“Major depres­sive dis­or­der affects near­ly 7 per­cent of peo­ple in the US aged 18 and up, accord­ing to the Depres­sion and Bipo­lar Sup­port Alliance. Those who seek treat­ment will most like­ly be pre­scribed a sec­ond-gen­er­a­tion anti­de­pres­sant med­ica­tion such as a selec­tive sero­tonin reup­take inhibitor (SSRI), tri­cyclic anti­de­pres­sant (TCA), or a monoamine oxi­dase inhibitor (MAOI). Some recent stud­ies, though, [Read more…] about Sys­tem­at­ic evi­dence review finds cog­ni­tive behav­ioral ther­a­py as effec­tive as anti­de­pres­sant med­i­cines in treat­ing depression